We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Big Pharma Stuck Between Investors and the Public

By LabMedica International staff writers
Posted on 24 Sep 2012
Big Pharma currently comes across a range of pressures from generics manufacturers, governments, patient advocacy groups, investors, physicians, and even other pharmaceutical or biotechnology firms. More...
In dealing with these pressures, companies are trying to focus upon the needs of their key stakeholder, the investors, or shareholders, according to recent market research.

As the timeframe of exclusivity shortens and regulatory requirements increase, companies are faced with declining profits and decreasing brand cachet, particularly in emerging markets, according to GlobalData, an international market research firm (London, UK). On top of this, they have to deal with reference pricing and rigorous healthcare cost controls being set up by various governments, particularly in Europe. According to Sanofi’s CEO, Chris Viehbacher, the financial situation in Europe has been costing Sanofi EUR 200-300 million a year as a result of governments’ healthcare spending cuts.

Sanofi has faced an interesting year in the limelight, with their latest hurdle being Sanofi’s pricing strategy in Japan coming under question. Sanofi’s IPV (inactivated poliovirus vaccine) Imovax Polio SC injection is currently priced at almost JPY 5,500 per syringe, which comes at an almost 270% price premium compared to the cost of the same vaccine in the United States. Japanese officials at the Ministry of Health, Labor, and Welfare (MHLW) have issued repeated letters to the executive board of the pharmaceutical behemoth, requesting that they revise prices prior to entry into the market.

Sanofi’s executives have held fast, and have issued strong statements to indicate that the price points instated for the IPVs were needed to recover costs incurred to enter the Japanese market. However, Sanofi faces the looming threat of new entrants from domestic combinatorial vaccine manufacturers that are ready to enter the market in the very near future, and will likely usurp Sanofi as the leading IPV vaccine manufacturer in Japan. Consequently, the company has little time to earn significant revenue from the sale of its polio vaccine in Japan.

In the case of vaccines, manufacturers are less and less inclined to invest because of reasons as simple as a poor business model. The vaccine segment, seen as a silver bullet by global health initiatives, is no cash cow for pharmaceutical companies. The one glitch to this oversimplification would be the influenza market, which benefits from antigenic shift of the virus, thereby resulting in the need for a new annual vaccine against the viral strain in circulation. As a company attempts to recoup costs of development, one sees this reflected in the price of each vaccine. However, as manufacturers reach superior levels of effectiveness with their vaccines, they are forced to substantiate the changing costs as patients move from one therapy to another, according to GlobalData analysts.

Now, one sees companies such as Sanofi that are finding themselves into a corner by a number of different stakeholders. Sanofi is currently in a lawsuit against physician buying groups, who maintain that Sanofi’s contracts imitate antitrust laws and limit healthy market competition. Novartis is also currently entangled in a lawsuit with Indian courts over the prices of cancer drug Gleevec, with the company emphasizing that most patients who participated in the trial did not have to pay out of pocket for the expensive drug treatment.

Gilead, a leader in HIV therapeutics, has similarly been pressured by health advocacy groups and other lobbyists to provide their therapies at a discount to patients in countries with a low annual gross domestic product (GDP). Gilead, potentially forced into responding to these claims, has surrendered to these external pressures, and agreed to participate in the transfer of technology to promote the distribution of their drugs as generics. In August 2012, the company signed deals with Mylan, Strides Arcolab, and Ranbaxy to manufacture low-cost generic versions of its HIV drug, Emtriva (emtricitabine).

Clearly, drug makers have to walk a fine line while attempting to please both investors and the public--two parties with contrasting expectations and demands. In spite of the efforts of companies like Gilead and Roche at running “access” programs, which aim to make their drugs affordable for developing countries, the public still winces at the massive profits announced by these drug makers every quarter. How profitable should pharmaceutical companies be in order to satisfy both sides? Should there be a limit to their profitability, keeping in mind the expensive, long, and risky drug development process? How do pharmaceutical companies validate that they care about patients if the very life-saving treatments they develop are too cost-prohibitive by those who need them the most? How involved should patient advocacy be in drug pricing, bearing in mind that with every “victory” they get, they come back with even more aggressive demands?

These are some of the imperative questions begging to be answered. Regardless of the enthusiasm shown during the launch of a new drug or vaccine, it all comes down to one thing in the end: pricing. Will pharmaceutical companies stand their ground or will they yield to the demands of the public? Sanofi has chosen the former, according to GlobalData, at least for now.

GlobalData is a global business intelligence provider. The company’s research and analysis is based on the expert knowledge of over 700 business analysts and 25,000 interviews conducted with industry insiders yearly.

Related Links:

GlobalData




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Microscope
dIFine
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.